This finding suggests that anti-HBc IgG positivity may adversely affect the course of the disease in ITP patients, leading to a longer and more severe disease course and potentially contributing to resistance to treatment. The gene discussed is KRT88P; the disease is autoimmune thrombocytopenic purpura.